Description
The antigen-presenting molecule MR1 has been shown to mediate anti-tumour immunity, with specific MR1-restricted T cells exhibiting pan-cancer killing activity while sparing healthy cells. Because MR1 has limited sequence variation and is highly conserved across individuals, MR1-targeted therapies are broadly applicable across the human population. This project will utilize computational, structural, and immunological approaches to develop MR1-based tools to harness the anti-tumour responses of T cells. Ultimately, this fundamental research aims to pave the way for universal, next-generation MR1-based anti-cancer therapeutics.
Essential criteria:
Minimum entry requirements can be found here: https://www.monash.edu/admissions/entry-requirements/minimum
Keywords
cancer, T cells, adaptive immunity, MR1, antigen presentation, protein crystallography
School
Biomedicine Discovery Institute (School of Biomedical Sciences) » Biochemistry and Molecular Biology
Available options
PhD/Doctorate
Masters by research
Honours
BMedSc(Hons)
Short projects
Joint PhD/Exchange Program
Time commitment
Full-time
Top-up scholarship funding available
No
Physical location
Biomedicine Discovery Institute
Research webpage